These therapies are based on monoclonal antibodies targeting immunomodulatory receptors such as cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) that modulate the activity of cytotoxic T cells, thereby triggering anti-tumor immune responses [25,26]. Here, CTLA4 is linked to neoplasm.